 The stock price of Inovio Pharmaceutic, a biotechnology company focused on synthetic DNA products for treating cancers and infectious diseases, reached its 52-week high levels of around 19 in February this year, before a large sell-off resulted in INO stock falling to levels of around 6 in April. 